The Siteman Cancer Center (SCC) combines excellence in clinical research, patient care and basic science to foster anenvironment in which novel solutions are developed for cancer-related health problems. The structure of theTranslational and Clinical Research program is designed to maximize these discoveries by establishing aninfrastructure for highly productive interchange between investigators in the basic science of malignancy, oncologicimaging, prevention and control and clinical trial development. During the previous three-year award period, theTranslational and Clinical Research Program developed a paradigm for integrating basic science research programswith disease-oriented focus groups, producing interdisciplinary, highly translational programs that will ultimately producemulti-project grants, such as Program Project Grants (P01s) or SPOREs. This is demonstrated through thedevelopment of the newly-named Hematopoietic Development and Malignancy Program, which has united the old StemCell Biology Program and the Leukemia/Lymphoma/Transplant Focus Group of this program. The goals of theTranslational and Clinical Research Program are as follows: To develop new translational research programs that will ultimately produce multi-project grants (such asSPOREs and P01s) through the integration of Focus Groups with the Basic Science, Prevention and Control,and Oncologic Imaging Programs. To develop, prioritize and execute novel investigator-initiated clinical trials with a particular emphasis ontranslational research that involves collaborators from the Basic Science, Prevention and Control, andOncologic Imaging programs and is driven by the four central scientific themes of cancer genetics, cancerbiology and development, innovative diagnostics and therapeutics, and chemoprevention. To participate in important NCI-sponsored clinical trials addressing questions that can only be answered in thesetting of multi-institutional Phase III trials. To collaborate with members of the pharmaceutical industry to develop and test novel compounds that requirepharmacologic and molecular expertise that can be uniquely provided by the SCC. To develop multidisciplinary clinical care and research programs that encourage contribution from all membersof the oncology professional community (treating physicians, basic science researchers, psychologists, nurses,etc.).
Showing the most recent 10 out of 1244 publications
